I-01 Leon Aarons
Population Pharmacokinetic Analysis of Ropivacaine and its Metabolite PPX from Pooled Data in Neonates, Infants and Children
Wednesday 10:15-11:45 |
I-04 Hesham Al-Sallami
A semi-mechanistic model for estimating fat free mass in children
Wednesday 10:15-11:45 |
I-27 Marion Bouillon-Pichault
Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4
Wednesday 10:15-11:45 |
I-36 Massimo Cella
Implementation of Pharmacokinetic Bridging for Drug Combinations in Children
Wednesday 10:15-11:45 |
I-38 Pascal Chanu
A dose selection rationale based on hemodynamics for sildenafil in pediatric patients with pulmonary arterial hypertension (PAH)
Wednesday 10:15-11:45 |
I-48 Karina Blei
Evaluation of a PBPK Model for Preterm Neonates by Predicting Paracetamol Pharmacokinetics
Wednesday 10:15-11:45 |
II-05 Cyrielle Dumont
Design optimisation of a pharmacokinetic study in the paediatric development of a drug
Wednesday 14:55-16:10 |
II-08 Esther Encinas
Fentanyl pharmacokinetic and pharmacodynamic (PK/PD) estimation in neonates and infants using allometric and ontogeny methods
Wednesday 14:55-16:10 |
II-12 David Fabre
Population Pharmacokinetics of Alfusozin in children and adolescents
Wednesday 14:55-16:10 |
II-32 Andreas Velsing Groth
Predicting paediatric PK in order to investigate it
Wednesday 14:55-16:10 |
II-39 Anna-Karin Hamberg
Predictions of warfarin exposure and INR response in children
Wednesday 14:55-16:10 |
II-41 Sarapee Hirankarn
Population K-PD Model of Sodium Nitroprusside in Neonates and Children During Anesthesia or Sedation
Wednesday 14:55-16:10 |
II-45 Ibrahim Ince
Population PK of midazolam from preterm neonates to adults, a maturation model
Wednesday 14:55-16:10 |
II-56 Nastya Kassir
An Optimal Sampling Strategy for Tacrolimus in Pediatric Liver Transplant Recipients Based on a Population Pharmacokinetic Model
Wednesday 14:55-16:10 |
II-63 Sung Eun Kim
Population Pharmacokinetics of Theophylline in Premature Korean Infants
Wednesday 14:55-16:10 |
II-64 Holly Kimko
Disease-Drug Model of Methylphenidate (MPH) in Children with Attention Deficit Hyperactivity Disorder Via Longitudinal Meta-analysis
Wednesday 14:55-16:10 |
III-03 Elke Krekels
Maturation of glucuronidation; a system specific property
Thursday 09:50-11:05 |
III-20 Amelie Marsot
Population pharmacokinetics of Phenobarbital in neonates and infants.
Thursday 09:50-11:05 |
III-45 Parul Patel
Dried Blood Spots and Sparse Sampling: A perfect combination for minimally invasive PK/PD studies in children
Thursday 09:50-11:05 |
III-53 Chiara Piana
Impact of non-adherence to antiretroviral therapy in HIV-infected children
Thursday 09:50-11:05 |
IV-10 Ivy Song
Dose Selection of Dolutegravir (DTG, S/GSK1349572) in Pediatric Studies
Thursday 15:05-16:20 |
IV-31 Wanchana Ungphakorn
Population Pharmacokinetics and Use of Monte Carlo Simulation To Determine Optimal Dosing Regimen of Oral Ciprofloxacin in Paediatric Patients with Severe Malnutrition
Thursday 15:05-16:20 |
IV-33 Pyry Välitalo
Pharmacokinetics of Oxycodone in Labouring Women With Preliminary Estimates of Neonatal Exposure
Thursday 15:05-16:20 |
IV-39 Sven van Dijkman
Optimal design for a dexmedetomidine pharmacokinetic trial in mechanically ventilated neonates with single organ respiratory failure.
Thursday 15:05-16:20 |
IV-44 Katarina Vučićević
Population Pharmacokinetic Modelling of Amikacin in Neonates
Thursday 15:05-16:20 |
IV-46 Chenguang Wang
The allometric exponent for propofol clearance varies with age
Thursday 15:05-16:20 |
IV-64 Wei Zhao
Individualized therapy and Bayesian estimator of ganciclovir exposure after oral administration of valganciclovir in pediatric renal transplant patients
Thursday 15:05-16:20 |
